Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey

Xenobiotica

Volumn 36, Issue 7, 2006, Pages 597-613

  Hemeryck, A ^a   Mamidi, R N V S ^b   Bottacini, M ^c   Macpherson, D ^c   Kao, M ^b   Kelley, M F ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Inveresk Research   (United Kingdom)

^d LLC   (United States)

Author keywords

Excretion; Levofloxacin; Metabolism; Pharmacokinetics; Plasma protein binding; Rhesus monkey

Indexed keywords

CARBON 14; DRUG METABOLITE; GLUCURONIDE; LEVOFLOXACIN; LEVOFLOXACIN N OXIDE; NORLEVOFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONJUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; FECES ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RHESUS MONKEY; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; CARBON RADIOISOTOPES; FEMALE; MACACA MULATTA; MALE; OFLOXACIN; PROTEIN BINDING;

ANIMALIA; MACACA MULATTA;

EID: 33746845271     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600674436     Document Type: Article

References (17)

1. Aminimanizani A, Beringer P, Jelliffe R. 2001. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Journal of Clinical Pharmacokinetics 40:169-187.
2. Athamna A, Massalha M, Athamna M, Nura A, Medlej B, Ofek I, Bast D, Rubinstein E. 2004. In vitro susceptibility of B. anthracis to various antimicrobial agents and their time-kill activity. Journal of Antimicrobial Chemotherapy 53:247-251.
3. Brook I. 2002. The prophylaxis and treatment of anthrax. International Journal of Antimicrobial Agents 20:320-325.
4. Brookmeyer R, Blades N. 2002. Prevention of inhalational anthrax in the U.S. Journal of Outbreak Science 295:1861.
5. Bryskier A. 2002. Bacillus anthracis and antibacterial agents. Journal of Clinical Microbiological Infections 8:467-478.
6. Bush K, Kao M, Barnewall R, Estep J, Hemeryck A, Kelley MF. 2003. Efficacy of levofloxacin in the inhalation anthrax (post-exposure) Rhesus monkey model. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Late-Breaker abstract 4539; Chicago, IL, USA.
7. Deziel MR, Heine H, Louie A, Kao M, Byrne WR, Basset J, Miller L, Bush K, Kelly MF, Drusano GL. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrobial Agents and Chemotherapy 49:5099-5106.
8. Fish D, Chow A. 1997. The clinical pharmacokinetics of levofloxacin. Journal of Clinical Pharmacokinetics 32:101-119.
9. Kao M, Chien S, Bush K, Thalacker F, Kelley MF. 2003. Pharmacokinetic considerations in levofloxacin dose selection for an inhalation anthrax (post-exposure) study in Rhesus monkeys. In: Abstracts of the 12th North American ISSX Meeting, Providence, RI, USA, abstract 123, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., NJ, USA.
10. Khan AS, Levitt AM, Sage MJ. 2000. Biological and chemical terrorism: Strategic plan for preparedness and response: Recommendations of the CDC Strategic Planning Workgroup. MMWR Recommendation Report 49(RR-4): 1-14.
11. Kihira T, Sato J, Shibata T. 2004. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis. Journal of Infections and Chemotherapy 10:97-100.
12. Shipova M, Armstrong VW, Oellerich M, Wieland E. 2003. Acyl glucuronide drug metabolites: Toxicological and analytical implications. Therapy and Drug Monitoring 25:1-16.
13. Sudo K, Okazaki O, Tsumura M, Tachizawa H. 1986. Isolation and identification of metabolites of ofloxacin in rats, dogs, and monkeys. Xenobiotica 16:725-732.
14. 14C-levofloxacin after a single oral administration in albino and pigmented rats: Binding characteristics of levofloxacin-related radioactivity to melanin in vivo. Journal of Pharmacology 56:463-469.
15. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2002. Draft guidance for industry, inhalation anthrax (post-exposure) - development of antimicrobial drugs. Washington, DC: US Food and Drug Administration.
16. Wong FA, Flor SC. 1990. The metabolism of ofloxacin in humans. Drug Metabolism and Disposition 18:1103-1104.
17. Zlotos G, Bucker A, Kinzig-Schippers M, Sorgel F, Holzgrabe U. 1998. Plasma protein binding of gyrase inhibitors. Pharmacology Sciences 87:215-220.